Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1843, Issue 11, 2014, Pages 2563-2582

  Turner, Mark D ^a   Nedjai, Belinda ^b   Hurst, Tara ^a   Pennington, Daniel J ^c  

^a NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Chemotaxis; Innate immunity; Interferon; Interleukin; Tumour necrosis factor

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CHEMOKINE; CHEMOKINE RECEPTOR; COLONY STIMULATING FACTOR 1; CYTOKINE; CYTOKINE RECEPTOR; ERYTHROPOIETIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC DISEASE; ALZHEIMER DISEASE; ASTHMA; AUTOINFLAMMATORY DISEASE; AUTOSOMAL RECESSIVE DISORDER; BEHCET DISEASE; CINCA SYNDROME; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FAMILIAL MEDITERRANEAN FEVER; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; IMMUNOPATHOGENESIS; INFLAMMATORY DISEASE; INTERLEUKIN 1 RECEPTOR ANTAGONIST DEFICIENCY; MEVALONATE KINASE DEFICIENCY; MEVALONIC ACIDURIA; MUCKLE WELLS SYNDROME; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

EID: 84905383217     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2014.05.014     Document Type: Review

References (306)

1. Ansar W., Ghosh S. C-reactive protein and the biology of disease. Immunol. Res. 2013, 56:131-142.
2. Laveti D., Kumar M., Hemalatha R., Sistla R., Naidu V.G., Talla V., Verma V., Kaur N., Nagpal R. Anti-inflammatory treatments for chronic diseases: a review. Inflamm. Allergy Drug Targets 2013, 12:349-361.
3. Boraschi D., Lucchesi D., Hainzl S., Leitner M., Maier E., Mangelberger D., Oostingh G.J., Pfaller T., Pixner C., Posselt G., Italiani P., Nold M.F., Nold-Petry C.A., Bufler P., Dinarello C.A. IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur. Cytokine Netw. 2011, 22:127-147.
4. Santarlasci V., Cosmi L., Maggi L., Liotta F., Annunziato F. IL-1 and T helper immune responses. Front. Immunol. 2013, 4:182.
5. Arend W.P., Palmer G., Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol. Rev. 2008, 223:20-38.
6. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 2009, 27:519-550.
7. Brennan K., Bowie A.G. Activation of host pattern recognition receptors by viruses. Curr. Opin. Microbiol. 2010, 13:503-507.
8. Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011, 34:637-650.
9. Casanova J.L., Abel L., Quintana-Murci L. Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Annu. Rev. Immunol. 2011, 29:447-491.
10. O'Neill L.A. The interleukin-1 receptor/Toll-like receptor superfamily: 10years of progress. Immunol. Rev. 2008, 226:10-18.
11. Elzinga B.M., Twomey C., Powell J.C., Harte F., McCarthy J.V. Interleukin-1 receptor type 1 is a substrate for gamma-secretase-dependent regulated intramembrane proteolysis. J. Biol. Chem. 2009, 284:1394-1409.
12. Arend W.P., Guthridge C.J. Biological role of interleukin 1 receptor antagonist isoforms. Ann. Rheum. Dis. 2000, 59(Suppl. 1):i60-i64.
13. Planck S.R., Woods A., Clowers J.S., Nicklin M.J., Rosenbaum J.T., Rosenzweig H.L. Impact of IL-1 signalling on experimental uveitis and arthritis. Ann. Rheum. Dis. 2012, 71:753-760.
14. Kautz-Neu K., Kostka S.L., Dinges S., Iwakura Y., Udey M.C., von Stebut E. A role for leukocyte-derived IL-1RA in DC homeostasis revealed by increased susceptibility of IL-1RA-deficient mice to cutaneous leishmaniasis. J. Invest. Dermatol. 2011, 131:1650-1659.
15. Gabay C., Lamacchia C., Palmer G. Il-1 pathways in inflammation and human diseases. Nat. Rev. Rheumatol. 2010, 6:232-241.
16. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. U. S. A. 1975, 72:3666-3670.
17. Aggarwal B.B., Kohr W.J., Hass P.E., Moffat B., Spencer S.A., Henzel W.J., Bringman T.S., Nedwin G.E., Goeddel D.V., Harkins R.N. Human tumor necrosis factor. Production, purification, and characterization. J. Biol. Chem. 1985, 260:2345-2354.
18. Pennica D., Nedwin G.E., Hayflick J.S., Seeburg P.H., Derynck R., Palladino M.A., Kohr W.J., Aggarwal B.B., Goeddel D.V. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984, 312:724-729.
19. Tartaglia L.A., Goeddel D.V. Two TNF receptors. Immunol. Today 1992, 13:151-153.
20. Rothe J., Gehr G., Loetscher H., Lesslauer W. Tumor necrosis factor receptors-structure and function. Immunol. Res. 1992, 11:81-90.
21. Smith C.A., Farrah T., Goodwin R.G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994, 76:959-962.
22. Locksley R.M., Killeen N., Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001, 104:487-501.
23. Gupta S. Tumor necrosis factor-alpha-induced apoptosis in T cells from aged humans: a role of TNFR-I and downstream signaling molecules. Exp. Gerontol. 2002, 37:293-299.
24. Lobito A.A., Gabriel T.L., Medema J.P., Kimberley F.C. Disease causing mutations in the TNF and TNFR superfamilies: focus on molecular mechanisms driving disease. Trends Mol. Med. 2011, 17:494-505.
25. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 2008, 117:244-279.
26. Stow J.L., Low P.C., Offenhäuser C., Sangermani D. Cytokine secretion in macrophages and other cells: pathways and mediators. Immunobiology 2009, 214:601-612.
27. MacEwan D.J. TNF receptor subtype signalling: differences and cellular consequences. Cell. Signal. 2002, 14:477-492.
28. Hehlgans T., Männel D.N. The TNF-TNF receptor system. Biol. Chem. 2002, 383:1581-1585.
29. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., Castner B.J., Stocking K.L., Reddy P., Srinivasan S., Nelson N., Boiani N., Schooley K.A., Gerhart M., Davis R., Fitzner J.N., Johnson R.S., Paxton R.J., March C.J., Cerretti D.P. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997, 385:729-733.
30. Friedmann E., Hauben E., Maylandt K., Schleeger S., Vreugde S., Lichtenthaler S.F., Kuhn P.H., Stauffer D., Rovelli G., Martoglio B. SPPL2a and SPPL2b promote intramembrane proteolysis of TNFα in activated dendritic cells to trigger IL-12 production. Nat. Cell Biol. 2006, 8:843-848.
31. Bradley J.R. TNF-mediated inflammatory disease. J. Pathol. 2008, 214:149-160.
32. Peschon J.J., Torrance D.S., Stocking K.L., Glaccum M.B., Otten C., Willis C.R., Charrier K., Morrissey P.J., Ware C.B., Mohler K.M. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J. Immunol. 1998, 160:943-952.
33. Chan F.K., Chun H.J., Zheng L., Siegel R.M., Bui K.L., Lenardo M.J. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000, 288:2351-2354.
34. Pobezinskaya Y.L., Kim Y.S., Choksi S., Morgan M.J., Li T., Liu C., Liu Z. The function of TRADD in signaling through tumor necrosis factor receptor 1 and TRIF-dependent Toll-like receptors. Nat. Immunol. 2008, 9:1047-1054.
35. Micheau O., Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003, 114:181-190.
36. Grell M., Douni E., Wajant H., Löhden M., Clauss M., Maxeiner B., Georgopoulos S., Lesslauer W., Kollias G., Pfizenmaier K., Scheurich P. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80kDa tumor necrosis factor receptor. Cell 1995, 83:793-802.
37. MacFarlane S.M., Pashmi G., Connell M.C., Littlejohn A.F., Tucker S.J., Vandenabeele P., MacEwan D.J. Differential activation of nuclear factor-kappaB by tumour necrosis factor receptor subtypes. TNFR1 predominates whereas TNFR2 activates transcription poorly. FEBS Lett. 2002, 515:119-126.
38. Moosmayer D., Dinkel A., Gerlach E., Hessabi B., Grell M., Pfizenmaier K., Scheurich P. Coexpression of the human TNF receptors TR60 and TR80 in insect cells: analysis of receptor complex formation. Lymphokine Cytokine Res. 1994, 13:295-301.
39. Müllberg J., Althoff K., Jostock T., Rose-John S. The importance of shedding of membrane proteins for cytokine biology. Eur. Cytokine Netw. 2000, 11:27-38.
40. Porteu F., Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophils. J. Exp. Med. 1990, 172:599-607.
41. Sakimoto T., Yamada A., Sawa M. Release of soluble tumor necrosis factor receptor 1 from corneal epithelium by TNF-alpha-converting enzyme-dependent ectodomain shedding. Invest. Ophthalmol. Vis. Sci. 2009, 50:4618-4621.
42. Jiang Y., Woronicz J.D., Liu W., Goeddel D.V. Prevention of constitutive TNF receptor 1 signaling by silencer of death domains. Science 1999, 283:543-546.
43. Peters M., Müller A.M., Rose-John S. Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood 1998, 92:3495-3504.
44. Jücker M., Abts H., Li W., Schindler R., Merz H., Günther A., von Kalle C., Schaadt M., Diamantstein T., Feller A.C. Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease. Blood 1991, 77:2413-2418.
45. Kishimoto T. IL-6: from its discovery to clinical applications. Int. Immunol. 2010, 22:347-352.
46. Smith K.A., Maizels R.M. IL-6 controls susceptibility to helminth infection by impeding Th2 responsiveness and altering the Treg phenotype in vivo. Eur. J. Immunol. 2014, 44:150-161.
47. Takeda K., Kaisho T., Yoshida N., Takeda J., Kishimoto T., Akira S. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J. Immunol. 1998, 161:4652-4660.
48. Gauldie J., Richards C., Northemann W., Fey G., Baumann H. IFN beta 2/BSF2/IL-6 is the monocyte-derived HSF that regulates receptor-specific acute phase gene regulation in hepatocytes. Ann. N. Y. Acad. Sci. 1989, 557:46-58.
49. Hirano T., Yasukawa K., Harada H., Taga T., Watanabe Y., Matsuda T., Kashiwamura S., Nakajima K., Koyama K., Iwamatsu A., Tsunasawa S., Sakiyama F., Matsui H., Takahara Y., Taniguchi T., Kishimoto T. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986, 324:73-76.
50. Parekh R.B., Dwek R.A., Rademacher T.W., Opdenakker G., Van Damme J. Glycosylation of interleukin-6 purified from normal human blood mononuclear cells. Eur. J. Biochem. 1992, 203:135-141.
51. Taga T., Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 1997, 15:797-819.
52. Goette N.P., Lev P.R., Heller P.G., Glembotsky A.C., Chazarreta C.D., Salim J.P., Molinas F.C., Marta R.F. Abnormal regulation of soluble and anchored IL-6 receptor in monocytes from patients with essential thrombocythemia. Exp. Hematol. 2010, 38:868-876.
53. Jostock T., Müllberg J., Ozbek S., Atreya R., Blinn G., Voltz N., Fischer M., Neurath M.F., Rose-John S. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur. J. Biochem. 2001, 268:160-167.
54. Graf D., Haselow K., Münks I., Bode J.G., Häussinger D. Caspase-mediated cleavage of the signal-transducing IL-6 receptor subunit gp130. Arch. Biochem. Biophys. 2008, 477:330-338.
55. Constantin G., Majeed M., Giagulli C., Piccio L., Kim J.Y., Butcher E.C., Laudanna C. Chemokines trigger immediate beta2 integrin affinity and mobility changes: differential regulation and roles in lymphocyte arrest under flow. Immunity 2000, 13:759-769.
56. Moser B., Wolf M., Walz A., Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 2004, 25:75-84.
57. Nomiyama H., Osada N., Yoshie O. Systematic classification of vertebrate chemokines based on conserved synteny and evolutionary history. Genes Cells 2013, 18:1-16.
58. Kelner G.S., Kennedy J., Bacon K.B., Kleyensteuber S., Largaespada D.A., Jenkins N.A., Copeland N.G., Bazan J.F., Moore K.W., Schall T.J. Lymphotactin: a cytokine that represents a new class of chemokine. Science 1994, 266:1395-1399.
59. Bazan J.F., Bacon K.B., Hardiman G., Wang W., Soo K., Rossi D., Greaves D.R., Zlotnik A., Schall T.J. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997, 385:640-644.
60. Thelen M. Dancing to the tune of chemokines. Nat. Immunol. 2001, 2:129-134.
61. Isik N., Hereld D., Jin T. Fluorescence resonance energy transfer imaging reveals that chemokine-binding modulates heterodimers of CXCR4 and CCR5 receptors. PLoS One 2008, 3:e3424.
62. Borroni E.M., Bonecchi R. Shaping the gradient by nonchemotactic chemokine receptors. Cell Adh. Migr. 2009, 3:146-147.
63. Pruenster M., Mudde L., Bombosi P., Dimitrova S., Zsak M., Middleton J., Richmond A., Graham G.J., Segerer S., Nibbs R.J., Rot A. The Duffy antigen receptor for chemokines transports chemokines and supports their promigratory activity. Nat. Immunol. 2009, 10:101-108.
64. + T helper 1 cell differentiation. Immunity 2012, 37:1091-1103.
65. Baggiolini M. Chemokines in pathology and medicine. J. Intern. Med. 2001, 250:91-104.
66. Sarmiento J., Shumate C., Suetomi K., Ravindran A., Villegas L., Rajarathnam K., Navarro J. Diverging mechanisms of activation of chemokine receptors revealed by novel chemokine agonists. PLoS One 2012, 7.
67. Lee W.Y., Wang C.J., Lin T.Y., Hsiao C.L., Luo C.W. CXCL17, an orphan chemokine, acts as a novel angiogenic and anti-inflammatory factor. Am. J. Physiol. Endocrinol. Metab. 2013, 304:E32-E40.
68. Kryczek I., Wei S., Keller E., Liu R., Zou W. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am. J. Physiol. Cell Physiol. 2007, 292:C987-C995.
69. Schroder K., Zhou R., Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger?. Science 2010, 327:296-300.
70. Maedler K., Sergeev P., Ris F., Oberholzer J., Joller-Jemelka H.I., Spinas G.A., Kaiser N., Halban P.A., Donath M.Y. Glucose-induced beta cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 2002, 110:851-860.
71. Donath M.Y., Böni-Schnetzler M., Ellingsgaard H., Halban P.A., Ehses J.A. Cytokine production by islets in health and diabetes: cellular origin, regulation and function. Trends Endocrinol. Metab. 2010, 21:261-267.
72. Eguchi K., Manabe I. Macrophages and islet inflammation in type 2 diabetes. Diabetes Obes. Metab. 2013, 15(Suppl. 3):152-158.
73. Suk K., Kim S., Kim Y.H., Kim K.A., Chang I., Yagita H., Shong M., Lee M.S. IFN-gamma/TNF-alpha synergism as the final effector in autoimmune diabetes: a key role for STAT1/IFN regulatory factor-1 pathway in pancreatic beta cell death. J. Immunol. 2001, 166:4481-4489.
74. Lee M.S. Cytokine synergism in apoptosis: its role in diabetes and cancer. J. Biochem. Mol. Biol. 2002, 35:54-60.
75. Miller E.J., Cohen A.B., Nagao S., Griffith D., Maunder R.J., Martin T.R., Weiner-Kronish J.P., Sticherling M., Christophers E., Matthay M.A. Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality. Am. Rev. Respir. Dis. 1992, 146:427-432.
76. Baggiolini M., Imboden P., Detmers P. Neutrophil activation and the effects of interleukin-8/neutrophil-activating peptide 1 (IL-8/NAP-1). Cytokines 1992, 4:1-17.
77. Mukaida N., Shiroo M., Matsushima K. Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8. J. Immunol. 1989, 143:1366-1371.
78. Hall D.A., Beresford I.J., Browning C., Giles H. Signalling by CXC-chemokine receptors 1 and 2 expressed in CHO cells: a comparison of calcium mobilization, inhibition of adenylyl cyclase and stimulation of GTPγS binding induced by IL-8 and GROα. Br. J. Pharmacol. 1999, 126:810-818.
79. Heidemann J., Ogawa H., Dwinell M.B., Rafiee P., Maaser C., Gockel H.R., Otterson M.F., Ota D.M., Lugering N., Domschke W., Binion D.G. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J. Biol. Chem. 2003, 278:8508-8515.
80. Hammond M.E., Lapointe G.R., Feucht P.H., Hilt S., Gallegos C.A., Gordon C.A., Giedlin M.A., Mullenbach G., Tekamp-Olson P. IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors. J. Immunol. 1995, 155:1428-1433.
81. Das S.T., Rajagopalan L., Guerrero-Plata A., Sai J., Richmond A., Garofalo R.P., Rajarathnam K. Monomeric and dimeric CXCL8 are both essential for in vivo neutrophil recruitment. PLoS One 2010, 5:e11754.
82. Schlorke D., Thomas L., Samsonov S.A., Huster D., Arnhold J., Pichert A. The influence of glycosaminoglycans on IL-8-mediated functions of neutrophils. Carbohydr. Res. 2012, 356:196-203.
83. Faurschou M., Borregaard N. Neutrophil granules and secretory vesicles in inflammation. Microbes Infect. 2003, 5:1317-1327.
84. Takami M., Terry V., Petruzzelli L. Signaling pathways involved in IL-8-dependent activation of adhesion through Mac-1. J. Immunol. 2002, 168:4559-4566.
85. Aggarwal B.B., Puri R.K. Human Cytokines: Their Role in Disease and Therapy 1994, Blackwell, Boston. B.B. Aggarwal, R.K. Puri (Eds.).
86. Rosa J.S., Flores R.L., Oliver S.R., Pontello A.M., Zaldivar F.P., Galassetti P.R. Sustained IL-1alpha, IL-4, and IL-6 elevations following correction of hyperglycemia in children with type 1 diabetes mellitus. Pediatr. Diabetes 2008, 9:9-16.
87. Park J.Y., Pillinger M.H. Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull. NYU Hosp. Jt. Dis. 2007, 65(Suppl. 1):S4-S10.
88. Portugal-Cohen M., Horev L., Ruffer C., Schlippe G., Voss W., Ma'or Z., Oron M., Soroka Y., Frušić-Zlotkin M., Milner Y., Kohen R. Non-invasive skin biomarkers quantification of psoriasis and atopic dermatitis: cytokines, antioxidants and psoriatic skin auto-fluorescence. Biomed. Pharmacother. 2012, 66:293-299.
89. Brugos B., Vincze Z., Sipka S., Szegedi G., Zeher M. Serum and urinary cytokine levels of SLE patients. Pharmazie 2012, 67:411-413.
90. Kawaguchi Y., Hara M., Wright T.M. Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J. Clin. Invest. 1999, 103:1253-1260.
91. Roach D.R., Bean A.G., Demangel C., France M.P., Briscoe H., Britton W.J. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J. Immunol. 2002, 168:4620-4627.
92. Feldmann M., Maini R.N. Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us?. J. Immunol. 2010, 185:791-794.
93. Seitz M., Dewald B., Ceska M., Gerber N., Baggiolini M. Interleukin-8 in inflammatory rheumatic diseases: synovial fluid levels, relation to rheumatoid factors, production by mononuclear cells, and effects of gold sodium thiomalate and methotrexate. Rheumatol. Int. 1992, 12:159-164.
94. Mahida Y.R., Ceska M., Effenberger F., Kurlak L., Lindley I., Hawkey C.J. Enhanced synthesis of neutrophil-activating peptide-1/interleukin-8 in active ulcerative colitis. Clin. Sci. (Lond.) 1992, 82:273-275.
95. + T lymphocytes. FASEB J. 1994, 8:1055-1060.
96. Shadidi K.R., Aarvak T., Henriksen J.E., Natvig J.B., Thompson K.M. The chemokines CCL5, CCL2 and CXCL12 play significant roles in the migration of Th1 cells into rheumatoid synovial tissue. Scand. J. Immunol. 2003, 57:192-198.
97. Nanki T., Takada K., Komano Y., Morio T., Kanegane H., Nakajima A., Lipsky P.E., Miyasaka N. Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis. Arthritis Res. Ther. 2009, 11:R149.
98. Flier J., Boorsma D.M., van Beek P.J., Nieboer C., Stoof T.J., Willemze R., Tensen C.P. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J. Pathol. 2001, 194:398-405.
99. Savic S., Dickie L.J., Battellino M., McDermott M.F. Familial Mediterranean fever and related periodic fever syndromes/autoinflammatory diseases. Curr. Opin. Rheumatol. 2012, 24:103-112.
100. Aksentijevich I., Masters S.L., Ferguson P.J., Dancey P., Frenkel J., van Royen-Kerkhoff A., Laxer R., Tedgård U., Cowen E.W., Pham T.H., Booty M., Estes J.D., Sandler N.G., Plass N., Stone D.L., Turner M.L., Hill S., Butman J.A., Schneider R., Babyn P., El-Shanti H.I., Pope E., Barron K., Bing X., Laurence A., Lee C.C., Chapelle D., Clarke G.I., Ohson K., Nicholson M., Gadina M., Yang B., Korman B.D., Gregersen P.K., van Hagen P.M., Hak A.E., Huizing M., Rahman P., Douek D.C., Remmers E.F., Kastner D.L., Goldbach-Mansky R. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 2009, 360:2426-2437.
101. Farasat S., Aksentijevich I., Toro J.R. Autoinflammatory diseases: clinical and genetic advances. Arch. Dermatol. 2008, 144:392-402.
102. Tidow N., Chen X., Müller C., Kawano S., Gombart A.F., Fischel-Ghodsian N., Koeffler H.P. Hematopoietic-specific expression of MEFV, the gene mutated in familial Mediterranean fever, and subcellular localization of its corresponding protein, pyrin. Blood 2000, 95:1451-1455.
103. Sohar E., Gafni J., Pras M., Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am. J. Med. 1967, 43:227-253.
104. Baykal Y., Saglam K., Yilmaz M.I., Taslipinar A., Akinci S.B., Inal A. Serum sIL-2r, IL-6, IL-10 and TNF-alpha level in familial Mediterranean fever patients. Clin. Rheumatol. 2003, 22:99-101.
105. Gang N., Drenth J.P., Langevitz P., Zemer D., Brezniak N., Pras M., van der Meer J.W., Livneh A. Activation of the cytokine network in familial Mediterranean fever. J. Rheumatol. 1999, 26:890-897.
106. Poland D.C., Drenth J.P., Rabinovitz E., Livneh A., Bijzet J., van het Hof B., van Dijk W. Specific glycosylation of alpha(1)-acid glycoprotein characterises patients with familial Mediterranean fever and obligatory carriers of MEFV. Ann. Rheum. Dis. 2001, 60:777-780.
107. Korkmaz C., Ozdogan H., Kasapçopur O., Yazici H. Acute phase response in familial Mediterranean fever. Ann. Rheum. Dis. 2002, 61:79-81.
108. Lachmann H.J., Goodman H.J., Gilbertson J.A., Gallimore J.R., Sabin C.A., Gillmore J.D., Hawkins P.N. Natural history and outcome in systemic AA amyloidosis. N. Engl. J. Med. 2007, 356:2361-2371.
109. Altunoǧlu A., Erten Ş., Canoz M.B., Yuksel A., Ceylan G.G., Balci S., Dogan H.T. Phenotype 2 familial Mediterranean fever: evaluation of 22 case series and review of the literature on phenotype 2 FMF. Ren. Fail. 2013, 35:226-230.
110. Marek-Yagel D., Berkun Y., Padeh S., Abu A., Reznik-Wolf H., Livneh A., Pras M., Pras E. Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis Rheum. 2009, 60:1862-1866.
111. Tunca M., Kirkali G., Soyturk M., Akar S., Pepys M.B., Hawkins P.N. Acute phase response and evolution of familial Mediterranean fever. Lancet 1999, 353:1415.
112. Ben-Chetrit E., Cohen R., Chajek-Shaul T. Familial Mediterranean fever and Behçet's disease-are they associated?. J. Rheumatol. 2002, 29:530-534.
113. Ozen S., Bakkaloglu A., Yilmaz E., Duzova A., Balci B., Topaloglu R., Besbas N. Mutations in the gene for familial Mediterranean fever: do they predispose to inflammation?. J. Rheumatol. 2003, 30:2014-2018.
114. James L.C., Keeble A.H., Khan Z., Rhodes D.A., Trowsdale J. Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:6200-6205.
115. Hesker P.R., Nguyen M., Kovarova M., Ting J.P., Koller B.H. Genetic loss of murine pyrin, the familial Mediterranean fever protein, increases interleukin-1β levels. PLoS One 2012, 7:e51105.
116. Williamson L.M., Hull D., Mehta R., Reeves W.G., Robinson B.H., Toghill P.J. Familial Hibernian fever. Q. J. Med. 1982, 51:469-480.
117. Kusuhara K., Nomura A., Nakao F., Hara T. Tumour necrosis factor receptor-associated periodic syndrome with a novel mutation in the TNFRSF1A gene in a Japanese family. Eur. J. Pediatr. 2004, 163:30-32.
118. Hull K.M., Drewe E., Aksentijevich I., Singh H.K., Wong K., McDermott E.M., Dean J., Powell R.J., Kastner D.L. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 2002, 81:349-368.
119. McDermott E.M., Smillie D.M., Powell R.J. Clinical spectrum of familial Hibernian fever: a 14-year follow-up study of the index case and extended family. Mayo Clin. Proc. 1997, 72:806-817.
120. McDermott M.F., Ogunkolade B.W., McDermott E.M., Jones L.C., Wan Y., Quane K.A., McCarthy J., Phelan M., Molloy M.G., Powell R.J., Amos C.I., Hitman G.A. Linkage of familial Hibernian fever to chromosome 12p13. Am. J. Hum. Genet. 1998, 62:1446-1451.
121. Mulley J., Saar K., Hewitt G., Rüschendorf F., Phillips H., Colley A., Sillence D., Reis A., Wilson M. Gene localization for an autosomal dominant familial periodic fever to 12p13. Am. J. Hum. Genet. 1998, 62:884-889.
122. McDermott M.F., Aksentijevich I., Galon J., McDermott E.M., Ogunkolade B.W., Centola M., Mansfield E., Gadina M., Karenko L., Pettersson T., McCarthy J., Frucht D.M., Aringer M., Torosyan Y., Teppo A.M., Wilson M., Karaarslan H.M., Wan Y., Todd I., Wood G., Schlimgen R., Kumarajeewa T.R., Cooper S.M., Vella J.P., Amos C.I., Mulley J., Quane K.A., Molloy M.G., Ranki A., Powell R.J., Hitman G.A., O'Shea J.J., Kastner D.L. TNFR1 define a family of dominantly inherited autoinflammatory syndromes. Cell 1999, 97:133-144.
123. Turner M.D., Chaudhry A., Nedjai B. TNFR1 trafficking dysfunction opens the TRAPS door to proinflammatory cytokine secretion. Biosci. Rep. 2012, 32:105-112.
124. Nedjai B., Hitman G.A., Yousaf N., Chernajovsky Y., Stjernberg S., Pettersson T., Turner M.D. Abnormal tumor necrosis factor receptor I cell surface expression and NF-κB activation in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 2008, 58:273-283.
125. Nedjai B., Hitman G.A., Church L.D., Minden K., Whiteford M.L., McKee S., Stjernberg S., Pettersson T., Ranki A., Hawkins P.N., Arkwright P.D., McDermott M.F., Turner M.D. Differential cytokine secretion results from p65 and c-Rel NF-κB subunit signaling in peripheral blood mononuclear cells of TNF receptor-associated periodic syndrome patients. Cell. Immunol. 2011, 268:55-59.
126. Jacobelli S., André M., Alexandra J.F., Dodé C., Papo T. Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology 2007, 46:1211-1212.
127. Drewe E., McDermott E.M., Powell P.T., Isaacs J.D., Powell R.J. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology 2003, 42:235-239.
128. Nedjai B., Hitman G.A., Quillinan N., Coughlan R.J., Church L.D., McDermott M.F., Turner M.D. Proinflammatory action of the antiinflammatory drug infliximab in TNF-receptor associated periodic syndrome. Arthritis Rheum. 2009, 60:619-625.
129. Churchman S.M., Church L.D., Savic S., Coulthard L.R., Hayward B., Nedjai B., Turner M.D., Mathews R.J., Baguley E., Hitman G.A., Gooi H.C., Wood P.M.D., Emery P., McDermott M.F. A novel TNFRSF1A splice mutation associated with increased NF-κB transcription factor activation in patients with TNF-receptor associated periodic syndrome (TRAPS). Ann. Rheum. Dis. 2008, 67:1589-1595.
130. Obici L., Meini A., Cattalini M., Chicca S., Galliani M., Donadei S., Plebani A., Merlini G. Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis. Ann. Rheum. Dis. 2011, 70:1511-1512.
131. Cattalini M., Meini A., Monari P., Gualdi G., Arisi M., Pelucchi F., Bolognini S., Gattorno M., Calzavara-Pinton P., Plebani A. Recurrent migratory angioedema as cutaneous manifestation in a familiar case of TRAPS: dramatic response to Anakinra. Dermatol. Online J. 2013, 19:20405.
132. Maedler K., Schumann D.M., Sauter N., Ellingsgaard H., Bosco D., Baertschiger R., Iwakura Y., Oberholzer J., Wollheim C.B., Gauthier B.R., Donath M.Y. Low concentration of interleukin-1β induces FLICE-inhibitory protein-mediated β-cell proliferation in human pancreatic islets. Diabetes 2006, 55:2713-2722.
133. Kitley J.L., Lachmann H.J., Pinto A., Ginsberg L. Neurologic manifestations of the cryopyrin-associated periodic syndrome. Neurology 2010, 74:1267-1270.
134. Feldmann J., Prieur A.M., Quartier P., Berquin P., Certain S., Cortis E., Teillac-Hamel D., Fischer A., de Saint Basile G. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am. J. Hum. Genet. 2002, 71:198-203.
135. Haneklaus M., O'Neill L.A.J., Coll R.C. Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments. Curr. Opin. Immunol. 2013, 25:40-45.
136. Aubert P., Suárez-Fariñas M., Mitsui H., Johnson-Huang L.M., Harden J.L., Pierson K.C., Dolan J.G., Novitskaya I., Coats I., Estes J., Cowen E.W., Plass N., Lee C.C., Sun H.W., Lowes M.A., Goldbach-Mansky R. Homeostatic tissue responses in skin biopsies from NOMID patients with constitutive overproduction of IL-1β. PLoS One 2012, 7:e49408.
137. Insalaco A., Prencipe G., Buonuomo P.S., Ceccherini I., Bracaglia C., Pardeo M., Nicolai R., De Benedetti F. A novel mutation in the CIAS1/NLRP3 gene associated with an unexpected phenotype of CAPS. Clin. Exp. Rheumatol. 2014, 32:123-125.
138. Hawkins P.N., Lachmann H.J., McDermott M.F. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N. Engl. J. Med. 2003, 348:2583-2584.
139. Hoffman H.M., Rosengren S., Boyle D.L., Cho J.Y., Nayar J., Mueller J.L., Anderson J.P., Wanderer A.A., Firestein G.S. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004, 364:1779-1785.
140. Goldbach-Mansky R., Dailey N.J., Canna S.W., Gelabert A., Jones J., Rubin B.I., Kim H.J., Brewer C., Zalewski C., Wiggs E., Hill S., Turner M.L., Karp B.I., Aksentijevich I., Pucino F., Penzak S.R., Haverkamp M.H., Stein L., Adams B.S., Moore T.L., Fuhlbrigge R.C., Shaham B., Jarvis J.N., O'Neil K., Vehe R.K., Beitz L.O., Gardner G., Hannan W.P., Warren R.W., Horn W., Cole J.L., Paul S.M., Hawkins P.N., Pham T.H., Snyder C., Wesley R.A., Hoffmann S.C., Holland S.M., Butman J.A., Kastner D.L. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N. Engl. J. Med. 2006, 355:581-592.
141. Clark W., Jobanputra P., Barton P., Burls A. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis. Health Technol. Assess. 2004, 8:1-105.
142. Economides A.N., Carpenter L.R., Rudge J.S., Wong V., Koehler-Stec E.M., Hartnett C., Pyles E.A., Xu X., Daly T.J., Young M.R., Fandl J.P., Lee F., Carver S., McNay J., Bailey K., Ramakanth S., Hutabarat R., Huang T.T., Radziejewski C., Yancopoulos G.D., Stahl N. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat. Med. 2003, 9:47-52.
143. Hoffman H.M. Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS). Expert. Opin. Biol. Ther. 2009, 9:519-531.
144. Goldbach-Mansky R., Shroff S.D., Wilson M., Snyder C., Plehn S., Barham B., Pham T.H., Pucino F., Wesley R.A., Papadopoulos J.H., Weinstein S.P., Mellis S.J., Kastner D.L. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum. 2008, 58:2432-2442.
145. Hoffman H.M., Throne M.L., Amar N.J., Sebai M., Kivitz A.J., Kavanaugh A., Weinstein S.P., Belomestnov P., Yancopoulos G.D., Stahl N., Mellis S.J. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 2008, 58:2443-2452.
146. Lachmann H.J., Jung T., Felix S.D., Lowe P., Offer M., Rordorf C., Hawkins P. Treatment of cryopyrin associated periodic fever syndrome with a fully human anti-IL-1beta monoclonal antibody (ACZ885): results from a subcutaneous administration study. Clin. Exp. Rheumatol. 2008, 26:181.
147. Lachmann H.J., Kone-Paut I., Kuemmerle-Deschner J.B., Leslie K.S., Hachulla E., Quartier P., Gitton X., Widmer A., Patel N., Hawkins P.N. Canakinumab in CAPS study group. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 2009, 360:2416-2425.
148. Ivker R.A., Grin-Jorgensen C.M., Vega V.K., Hoss D.M., Grant-Kels J.M. Infantile generalized pustular psoriasis associated with lytic lesions of the bone. Pediatr. Dermatol. 1993, 10:277-282.
149. Henderson C., Goldbach-Mansky R. Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: finding the right balance in response to danger signals. Clin. Immunol. 2010, 135:210-222.
150. Muzes G., Molnár B., Tulassay Z., Sipos F. Changes of the cytokine profile in inflammatory bowel diseases. World J. Gastroenterol. 2012, 18:5848-5861.
151. Manzo A., Caporali R., Montecucco C., Pitzalis C. Role of chemokines and chemokine receptors in regulating specific leukocyte trafficking in the immune/inflammatory response. Clin. Exp. Rheumatol. 2003, 21:501-508.
152. Nishimura M., Kuboi Y., Muramoto K., Kawano T., Imai T. Chemokines as novel therapeutic targets for inflammatory bowel disease. Ann. N. Y. Acad. Sci. 2009, 1173:350-356.
153. Eberhardson M., Marits P., Jones M., Jones P., Karlen P., Karlsson M., Cotton G., Woznica K., Maltman B., Glise H., Winqvist O. Treatment of inflammatory bowel disease by chemokine receptor-targeted leukapheresis. Clin. Immunol. 2013, 149:73-82.
154. Sartor R.B. Cytokines in intestinal inflammation: pathophysiologic and clinical considerations. Gastroenterology 1994, 106:533-539.
155. Elson C.O., Sartor R.B., Tennyson G., Riddel R. Experimental models of IBD. Gastroenterology 1995, 109:1344-1367.
156. Ahluwalia J.P. Immunotherapy in inflammatory bowel disease. Med. Clin. North Am. 2012, 96:525-544.
157. Rietdijk S.T., D'Haens G.R. Recent developments in the treatment of inflammatory bowel disease. J. Dig. Dis. 2013, 14:282-287.
158. Denmark V.K., Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update. Expert. Rev. Clin. Immunol. 2013, 9:77-92.
159. Danese S., Colombel J.F., Peyrin-Biroulet L., Rutgeerts P., Reinisch W. The role of anti-TNF in the management of ulcerative colitis - past, present and future. Aliment. Pharmacol. Ther. 2013, 37:855-866.
160. Feldmann M., Brennan F.M., Maini R.N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 1996, 14:397-440.
161. Moreland L.W., Baumgartner S.W., Schiff M.H., Tindall E.A., Fleischmann R.M., Weaver A.L., Ettlinger R.E., Cohen S., Koopman W.J., Mohler K., Widmer M.B., Blosch C.M. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 1997, 337:141-147.
162. Moreland L.W. Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis. Cleve. Clin. J. Med. 1999, 66:367-374.
163. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., DeWoody K.L., Schaible T.F., Rutgeerts P.J. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 1997, 337:1029-1035.
164. Pope S.M., Zimmermann N., Stringer K.F., Karow M.L., Rothenberg M.E. The eotaxin chemokines and CCR3 are fundamental regulators of allergen-induced pulmonary eosinophilia. J. Immunol. 2005, 175:5341-5350.
165. Ying S., Meng Q., Zeibecoglou K., Robinson D.S., Macfarlane A., Humbert M., Kay A.B. Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (Intrinsic) asthmatics. J. Immunol. 1999, 163:6321-6329.
166. Miotto D., Christodoulopoulos P., Olivenstein R., Taha R., Cameron L., Tsicopoulos A., Tonnel A.B., Fahy O., Lafitte J.J., Luster A.D., Wallaert B., Mapp C.E., Hamid Q. Expression of IFN-gamma-inducible protein; monocyte chemotactic proteins 1, 3, and 4; and eotaxin in TH1- and TH2-mediated lung diseases. J. Allergy Clin. Immunol. 2001, 107:664-670.
167. Medoff B.D., Sauty A., Tager A.M., Maclean J.A., Smith R.N., Mathew A., Dufour J.H., Luster A.D. IFN-gamma-inducible protein 10 (CXCL10) contributes to airway hyperreactivity and airway inflammation in a mouse model of asthma. J. Immunol. 2002, 168:5278-5286.
168. Gonzalo J.A., Lloyd C.M., Peled A., Delaney T., Coyle A.J., Gutierrez-Ramos J.C. Critical involvement of the chemotactic axis CXCR4/stromal cell-derived factor-1 alpha in the inflammatory component of allergic airway disease. J. Immunol. 2000, 165:499-508.
169. Venge J., Lampinen M., Håkansson L., Rak S., Venge P. Identification of IL-5 and RANTES as the major eosinophil chemoattractants in the asthmatic lung. J. Allergy Clin. Immunol. 1996, 97:1110-1115.
170. Nomura T., Terada N., Kim W.J., Nakano K., Fukuda Y., Wakita A., Numata T., Konno A. Interleukin-13 induces thymus and activation-regulated chemokine (CCL17) in human peripheral blood mononuclear cells. Cytokine 2002, 20:49-55.
171. Hartl D., Buckland K.F., Hogaboam C.M. Chemokines in allergic aspergillosis-from animal models to human lung diseases. Inflamm. Allergy Drug Targets 2006, 5:219-228.
172. Hartl D., Latzin P., Zissel G., Krane M., Krauss-Etschmann S., Griese M. Chemokines indicate allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2006, 173:1370-1376.
173. Leirisalo-Repo M. The present knowledge of the inflammatory process and the inflammatory mediators. Pharmacol. Toxicol. 1994, 75(Suppl. 2):1-3.
174. Leonard E.J., Yoshimura T. Neutrophil attractant/activation protein-1 (NAP-1 [interleukin-8]). Am. J. Respir. Cell Mol. Biol. 1990, 2:479-486.
175. Fulkerson P.C., Zimmermann N., Hassman L.M., Finkelman F.D., Rothenberg M.E. Pulmonary chemokine expression is coordinately regulated by STAT1, STAT6, and IFN-gamma. J. Immunol. 2004, 173:7565-7574.
176. + "regulatory" T-cell subtypes in atopic dermatitis reveals a novel T(H)2-like population. J. Allergy Clin. Immunol. 2008, 121:415-422.
177. + CD25(high) CD127(low/-) T cells in human allergic asthma. J. Immunol. 2008, 181:5386-5395.
178. Paovic J., Paovic P., Sredovic V. Behcet's disease: systemic and ocular manifestations. Biomed. Res. Int. 2013, 2013:247345.
179. Kulaber A., Tugal-Tutkun I., Yentür S.P., Akman-Demir G., Kaneko F., Gül A., Saruhan-Direskeneli G. Pro-inflammatory cellular immune response in Behçet's disease. Rheumatol. Int. 2007, 27:1113-1118.
180. Musabak U., Pay S., Erdem H., Simsek I., Pekel A., Dinc A., Sengul A. Serum interleukin-18 levels in patients with Behçet's disease. Is its expression associated with disease activity or clinical presentations?. Rheumatol. Int. 2006, 26:545-550.
181. Hamzaoui K., Hamzaoui A., Ghorbel I., Khanfir M., Houman H. Levels of IL-15 in serum and cerebrospinal fluid of patients with Behçet's disease. Scand. J. Rheumatol. 2006, 64:655-660.
182. Pay S., Şimşek I., Erdem H., Dinç A. Immunopathogenesis of Behçet's disease with special emphasize to the possible role of antigen presenting cells. Rheumatol. Int. 2007, 27:417-424.
183. Houman H., Hamzaoui A., Ben Ghorbal I., Khanfir M., Feki M., Hamzaoui K. Abnormal expression of chemokine receptors in Behçet's disease: relationship to intracellular Th1/Th2 cytokines and to clinical manifestations. J. Autoimmun. 2004, 23:267-273.
184. Bank I., Duvdevani M., Livneh A. Expansion of γδ T-cells in Behcet's disease: role of disease activity and microbial flora in oral ulcers. J. Lab. Clin. Med. 2003, 141:33-40.
185. Verjans G.M., van Hagen P.M., van der Kooi A., Osterhaus A.D., Baarsma G.S. Vγ9Vδ2 T cells recovered from eyes of patients with Behcet's disease recognize non-peptide prenyl pyrophosphate antigens. J. Neuroimmunol. 2002, 130:46-54.
186. Hasan A., Fortune F., Wilson A., Warr K., Shinnick T., Mizushima Y., van der Zee R., Stanford M.R., Sanderson J., Lehner T. Role of γδ T cells in pathogenesis and diagnosis of Behçet's disease. Lancet 1996, 347:789-794.
187. Frassanito M.A., Dammacco R., Cafforio P., Dammacco F. Th1 polarization of the immune response in Behcet's disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum. 1999, 42:1967-1974.
188. Verity D.H., Wallace G.R., Vaughan R.W., Stanford M.R. Behçet's disease - from Hippocrates to the third millennium. Br. J. Ophthalmol. 2003, 87:1175-1183.
189. Zierhut M., Mizuki N., Ohno S., Inoko H., Gül A., Onoé K., Isogai E. Immunology and functional genomics of Behçet's disease. Cell. Mol. Life Sci. 2003, 60:1903-1922.
190. Buchan G., Barrett K., Turner M., Chantry D., Maini R.N., Feldmann M. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin. Exp. Immunol. 1988, 73:449-455.
191. Brennan F.M., Chantry D., Jackson A., Maini R., Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989, 2:244-247.
192. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., Kollias G. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991, 10:4025-4031.
193. Brennan F.M., Gibbons D.L., Mitchell T., Cope A.P., Maini R.N., Feldmann M. Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints. Eur. J. Immunol. 1992, 22:1907-1912.
194. Elliott M.J., Maini R.N., Feldmann M., Kalden J.R., Antoni C., Smolen J.S., Leeb B., Breedveld F.C., Macfarlane J.D., Bijl H. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344:1105-1110.
195. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., van Zeben D., Kerstens P.J., Hazes J.M., Zwinderman A.H., Ronday H.K., Han K.H., Westedt M.L., Gerards A.H., van Groenendael J.H., Lems W.F., van Krugten M.V., Breedveld F.C., Dijkmans B.A. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2008, 58:S126-S135.
196. Tanaka Y. Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal?. Ann. Rheum. Dis. 2013, 72:ii124-ii127.
197. Garber K. Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market. Nat. Biotechnol. 2013, 31:3-4.
198. Sparks Stein P., Steffen M.J., Smith C., Jicha G., Ebersole J.L., Abner E., Dawson D. Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease. Alzheimers Dement. 2012, 8:196-203.
199. Kobayashi N., Nagata T., Shinagawa S., Oka N., Shimada K., Shimizu A., Tatebayashi Y., Yamada H., Nakayama K., Kondo K. Increase in the IgG avidity index due to herpes simplex virus type 1 reactivation and its relationship with cognitive function in amnestic mild cognitive impairment and Alzheimer's disease. Biochem. Biophys. Res. Commun. 2013, 430:907-911.
200. Alvarez G., Aldudo J., Alonso M., Santana S., Valdivieso F. Herpes simplex virus type 1 induces nuclear accumulation of hyperphosphorylated tau in neuronal cells. J. Neurosci. Res. 2012, 90:1020-1029.
201. Schütze S., Loleit T., Zeretzke M., Bunkowski S., Brück W., Ribes S., Nau R. Additive microglia-mediated neuronal injury caused by amyloid-β and bacterial TLR agonists in murine neuron-microglia co-cultures quantified by an automated image analysis using cognition network technology. J. Alzheimers Dis. 2012, 31:651-657.
202. Huang H.C., Jiang Z.F. Accumulated amyloid-beta peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease. J. Alzheimers Dis. 2009, 16:15-27.
203. Mrak R.E., Griffin W.S. Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol. Aging 2001, 22:903-908.
204. Mori T., Koyama N., Arendash G.W., Horikoshi-Sakuraba Y., Tan J., Town T. Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease. Glia 2010, 58:300-314.
205. Abraham C.R. Reactive astrocytes and alpha1-antichymotrypsin in Alzheimer's disease. Neurobiol. Aging 2001, 22:931-936.
206. Nilsson L.N., Das S., Potter H. Effect of cytokines, dexamethasone and the A/T-signal peptide polymorphism on the expression of alpha(1)-antichymotrypsin in astrocytes: significance for Alzheimer's disease. Neurochem. Int. 2001, 39:361-370.
207. Simic G., Lucassen P.J., Krsnik Z., Kruslin B., Kostovic I., Winblad B., Bogdanovi nNOS expression in reactive astrocytes correlates with increased cell death related DNA damage in the hippocampus and entorhinal cortex in Alzheimer's disease. Exp. Neurol. 2000, 165:12-26.
208. Hu J., Akama K.T., Krafft G.A., Chromy B.A., Van Eldik L.J. Amyloid-beta peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. Brain Res. 1998, 785:195-206.
209. Zhao J., O'Connor T., Vassar R. The contribution of activated astrocytes to Aβ production: implications for Alzheimer's disease pathogenesis. J. Neuroinflammation 2011, 8:150.
210. Tansey M.G., McCoy M.K., Frank-Cannon T.C. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp. Neurol. 2007, 208:1-25.
211. Bélanger M., Magistretti P.J. The role of astroglia in neuroprotection. Dialogues Clin. Neurosci. 2009, 11:281-295.
212. Farfara D., Lifshitz V., Frenkel D. Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J. Cell. Mol. Med. 2008, 12:762-780.
213. Tuppo E.E., Arias H.R. The role of inflammation in Alzheimer's disease. Int. J. Biochem. Cell Biol. 2005, 37:289-305.
214. Lossinsky A.S., Shivers R.R. Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Histol. Histopathol. 2004, 19:535-564.
215. Taupin P. Adult neurogenesis, neuroinflammation and therapeutic potential of adult neural stem cells. Int. J. Med. Sci. 2008, 5:127-132.
216. Das S., Basu A. Inflammation: a new candidate in modulating adult neurogenesis. J. Neurosci. Res. 2008, 86:1199-1208.
217. Nagele R.G., Wegiel J., Venkataraman V., Imaki H., Wang K.C., Wegiel J. Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. Neurobiol. Aging 2004, 25:663-674.
218. El Khoury J., Hickman S.E., Thomas C.A., Cao L., Silverstein S.C., Loike J.D. Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature 1996, 382:716-719.
219. Rogers J., Lue L.F. Microglial chemotaxis, activation, and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer's disease. Neurochem. Int. 2001, 39:333-340.
220. Simard A.R., Soulet D., Gowing G., Julien J.P., Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 2006, 49:489-502.
221. Lue L.F., Walker D.G., Brachova L., Beach T.G., Rogers J., Schmidt A.M., Stern D.M., Yan S.D. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp. Neurol. 2001, 171:29-45.
222. Tomozawa Y., Inoue T., Takahashi M., Adachi M., Satoh M. Apoptosis of cultured microglia by the deprivation of macrophage colony-stimulating factor. Neurosci. Res. 1996, 25:7-15.
223. Boissonneault V., Filali M., Lessard M., Relton J., Wong G., Rivest S. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease. Brain 2009, 132:1078-1092.
224. Wyss-Coray T., Loike J.D., Brionne T.C., Lu E., Anankov R., Yan F., Silverstein S.C., Husemann J. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat. Med. 2003, 9:453-457.
225. Koistinaho M., Lin S., Wu X., Esterman M., Koger D., Hanson J., Higgs R., Liu F., Malkani S., Bales K.R., Paul S.M. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat. Med. 2004, 10:719-726.
226. Johnstone M., Gearing A.J., Miller K.M. A central role for astrocytes in the inflammatory response to betaamyloid; chemokines, cytokines and reactive oxygen species are produced. J. Neuroimmunol. 1999, 93:182-193.
227. Smits H.A., Rijsmus A., van Loon J.H., Wat J.W., Verhoef J., Boven L.A., Nottet H.S. Amyloid-beta-induced chemokine production in primary human macrophages and astrocytes. J. Neuroimmunol. 2002, 127:160-168.
228. Mohamed A., Posse de Chaves E. Aβ internalization by neurons and glia. Int. J. Alzheimers Dis. 2011, 2011:127984.
229. Nagele R.G., D'Andrea M.R., Lee H., Venkataraman V., Wang H.Y. Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res. 2003, 971:197-209.
230. Tchelingerian J.L., Le Saux F., Jacque C. Identification and topography of neuronal cell populations expressing TNF alpha and IL-1 alpha in response to hippocampal lesion. J. Neurosci. Res. 1996, 43:99-106.
231. Friedman W.J. Cytokines regulate expression of the type 1 interleukin-1 receptor in rat hippocampal neurons and glia. Exp. Neurol. 2001, 168:23-31.
232. Li Y., Barger S.W., Liu L., Mrak R.E., Griffin W.S. S100beta induction of the proinflammatory cytokine interleukin-6 in neurons. J. Neurochem. 2000, 74:143-150.
233. De Haas A.H., Van Weering H.R., De Jong E.K., Boddeke H.W., Biber K.P. Neuronal chemokines: versatile messengers in central nervous system cell interaction. Mol. Neurobiol. 2007, 36:137-151.
234. Biber K., Vinet J., Boddeke H.W. Neuron-microglia signaling: chemokines as versatile messengers. J. Neuroimmunol. 2008, 198:69-74.
235. Mott R.T., Ait-Ghezala G., Town T., Mori T., Vendrame M., Zeng J., Ehrhart J., Mullan M., Tan J. Neuronal expression of CD22: novel mechanism for inhibiting microglial proinflammatory cytokine production. Glia 2004, 46:369-379.
236. Shen Y., Li R., McGeer E.G., McGeer P.L. Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res. 1997, 769:391-395.
237. Strohmeyer R., Shen Y., Rogers J. Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain. Brain Res. Mol. Brain Res. 2000, 81:7-18.
238. Yu J.X., Bradt B.M., Cooper N.R. Constitutive expression of proinflammatory complement components by subsets of neurons in the central nervous system. J. Neuroimmunol. 2002, 123:91-101.
239. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res. 2000, 887:80-89.
240. Davis S., Laroche S. What can rodent models tell us about cognitive decline in Alzheimer's disease?. Mol. Neurobiol. 2003, 27:249-276.
241. Moore A.H., Olschowka J.A., Williams J.P., Okunieff P., O'Banion M.K. Regulation of prostaglandin E2 synthesis after brain irradiation. Int. J. Radiat. Oncol. Biol. Phys. 2005, 62:267-272.
242. Pavlov V.A., Tracey K.J. The cholinergic anti-inflammatory pathway. Brain Behav. Immun. 2005, 19:493-499.
243. Heneka M.T., Wiesinger H., Dumitrescu-Ozimek L., Riederer P., Feinstein D.L., Klockgether T. Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2001, 60:906-916.
244. Schapira A.H. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. Neurology 2009, 72:S44-S50.
245. Martí M.J., Tolosa E. Parkinson disease: new guidelines for diagnosis of Parkinson disease. Nat. Rev. Neurol. 2013, 9:190-191.
246. Berardelli A., Wenning G.K., Antonini A., Berg D., Bloem B.R., Bonifati V., Brooks D., Burn D.J., Colosimo C., Fanciulli A., Ferreira J., Gasser T., Grandas F., Kanovsky P., Kostic V., Kulisevsky J., Oertel W., Poewe W., Reese J.P., Relja M., Ruzicka E., Schrag A., Seppi K., Taba P., Vidailhet M. EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. Eur. J. Neurol. 2013, 20:16-34.
247. Lees A.J., Hardy J., Revesz T. Parkinson's disease. Lancet 2009, 373:2055-2066.
248. McNaught K.S., Shashidharan P., Perl D.P., Jenner P., Olanow C.W. Aggresome-related biogenesis of Lewy bodies. Eur. J. Neurosci. 2002, 16:2136-2148.
249. Volpicelli-Daley L.A., Luk K.C., Patel T.P., Tanik S.A., Riddle D.M., Stieber A., Meaney D.F., Trojanowski J.Q., Lee V.M. Exogenous a-synuclein fibrils induce lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011, 72:57-71.
250. Yasuda T., Nakata Y., Mochizuki H. α-Synuclein and neuronal cell death. Mol. Neurobiol. 2013, 47:466-483.
251. Schapira A.H. Neurobiology and treatment of Parkinson's disease. Trends Pharmacol. Sci. 2009, 30:41-47.
252. Bonifati V. LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson's disease. Neurochem. Res. 2007, 32:1700-1708.
253. Lim K.L., Ng C.H. Genetic models of Parkinson disease. Biochim. Biophys. Acta 2009, 1792:604-615.
254. Lindqvist D., Hall S., Surova Y., Nielsen H.M., Janelidze S., Brundin L., Hansson O. Cerebrospinal fluid inflammatory markers in Parkinson's disease-associations with depression, fatigue, and cognitive impairment. Brain Behav. Immun. 2013, 33:183-189.
255. Nimmo A.J., Vink R. Recent patents in CNS drug discovery: the management of inflammation in the central nervous system. Recent Pat. CNS Drug Discov. 2009, 4:86-95.
256. Flood P.M., Qian L., Peterson L.J., Zhang F., Shi J.S., Gao H.M., Hong J.S. Transcriptional factor NF-κB as a target for therapy in Parkinson's disease. Parkinsons Dis. 2011, 2011:216298.
257. Imamura K., Hishikawa N., Sawada M., Nagatsu T., Yoshida M., Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol. 2003, 106:518-526.
258. Nagatsu T., Mogi M., Ichinose H., Togari A. Cytokines in Parkinson's disease. J. Neural Transm. Suppl. 2000, (58):143-151.
259. Barcia C., Fernández Barreiro A., Poza M., Herrero M.T. Parkinson's disease and inflammatory changes. Neurotox. Res. 2003, 5:411-418.
260. Hirsch E.C., Hunot S., Hartmann A. Neuroinflammatory processes in Parkinson's disease. Parkinsonism Relat. Disord. 2005, 11(Suppl. 1):S9-S15.
261. Arai H., Furuya T., Yasuda T., Miura M., Mizuno Y., Mochizuki H. Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1beta, and expression of caspase-11 in mice. J. Biol. Chem. 2004, 279:51647-51653.
262. Arai H., Furuya T., Mizuno Y., Mochizuki H. Inflammation and infection in Parkinson's disease. Histol. Histopathol. 2006, 21:673-678.
263. McCoy M.K., Martinez T.N., Ruhn K.A., Szymkowski D.E., Smith C.G., Botterman B.R., Tansey K.E., Tansey M.G. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J. Neurosci. 2006, 26:9365-9375.
264. Mattson M.P., Meffert M.K. Roles for NF-kappaB in nerve cell survival, plasticity, and disease. Cell Death Differ. 2006, 13:852-860.
265. Kaltschmidt B., Widera D., Kaltschmidt C. Signaling via NF-kappaB in the nervous system. Biochim. Biophys. Acta 2005, 1745:287-299.
266. Mattson M.P. NF-kappaB in the survival and plasticity of neurons. Neurochem. Res. 2005, 30:883-893.
267. Pizzi M., Spano P. Distinct roles of diverse nuclear factor-kappaB complexes in neuropathological mechanisms. Eur. J. Pharmacol. 2006, 545:22-28.
268. Hunot S., Brugg B., Ricard D., Michel P.P., Muriel M.-P., Ruberg M., Faucheux B.A., Agid Y., Hirsch E.C. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:7531-7536.
269. Liang Z.Q., Li Y.L., Zhao X.L., Han R., Wang X.X., Wang Y., Chase T.N., Bennett M.C., Qin Z.H. NF-kappaB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53. Brain Res. 2007, 1145:190-203.
270. Ghosh A., Roy A., Liu X., Kordower J.H., Mufson E.J., Hartley D.M., Ghosh S., Mosley R.L., Gendelman H.E., Pahan K. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:18754-18759.
271. Tran T.A., McCoy M.K., Sporn M.B., Tansey M.G. The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection. J. Neuroinflammation 2008, 5:14.
272. Yang L., Calingasan N.Y., Thomas B., Chaturvedi R.K., Kiaei M., Wille E.J., Liby K.T., Williams C., Royce D., Risingsong R., Musiek E.S., Morrow J.D., Sporn M., Beal M.F. Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS One 2009, 4:e5757.
273. Taylor J.M., Main B.S., Crack P.J. Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease. Neurochem. Int. 2013, 62:803-819.
274. Wersinger C., Sidhu A. Inflammation and Parkinson's disease. Curr. Drug Targets Inflamm. Allergy 2002, 1:221-242.
275. Liu B., Hong J.S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther. 2003, 304:1-7.
276. Sánchez-Pernaute R., Ferree A., Cooper O., Yu M., Brownell A.L., Isacson O. Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J. Neuroinflammation 2004, 1:6.
277. Gold B.G., Nutt J.G. Neuroimmunophilin ligands in the treatment of Parkinson's disease. Curr. Opin. Pharmacol. 2002, 2:82-86.
278. Kurkowska-Jastrzebska I., Litwin T., Joniec I., Ciesielska A., Przybyłkowski A., Członkowski A., Członkowska A. Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. Int. Immunopharmacol. 2004, 4:1307-1318.
279. Castaño A., Herrera A.J., Cano J., Machado A. The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. J. Neurochem. 2002, 81:150-157.
280. Du Y., Ma Z., Lin S., Dodel R.C., Gao F., Bales K.R., Triarhou L.C., Chernet E., Perry K.W., Nelson D.L., Luecke S., Phebus L.A., Bymaster F.P., Paul S.M. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:14669-14674.
281. He Y., Appel S., Le W. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res. 2001, 909:187-193.
282. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 2002, 22:1763-1771.
283. Tomás-Camardiel M., Rite I., Herrera A.J., de Pablos R.M., Cano J., Machado A., Venero J.L. Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. Neurobiol. Dis. 2004, 16:190-201.
284. Yang L., Sugama S., Chirichigno J.W., Gregorio J., Lorenzl S., Shin D.H., Browne S.E., Shimizu Y., Joh T.H., Beal M.F., Albers D.S. Minocycline enhances MPTP toxicity to dopaminergic neurons. J. Neurosci. Res. 2003, 74:278-285.
285. Diguet E., Fernagut P.O., Wei X., Du Y., Rouland R., Gross C., Bezard E., Tison F. Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur. J. Neurosci. 2004, 19:3266-3276.
286. NINDS NET-PD Investigators.The National Institute of Neurological Disorders and Stroke Neuroprotective Exploratory Trials in Parkinson's Disease Investigators A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006, 66:664-671.
287. Gordon P.H., Moore D.H., Miller R.G., Florence J.M., Verheijde J.L., Doorish C., Hilton J.F., Spitalny G.M., MacArthur R.B., Mitsumoto H., Neville H.E., Boylan K., Mozaffar T., Belsh J.M., Ravits J., Bedlack R.S., Graves M.C., McCluskey L.F., Barohn R.J., Tandan R., Western ALS Study Group Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007, 6:1045-1053.
288. Kim H.S., Suh Y.H. Minocycline and neurodegenerative diseases. Behav. Brain Res. 2009, 196:168-179.
289. Delgado M., Ganea D. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB J. 2003, 17:944-946.
290. Delgado M., Ganea D. Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma. FASEB J. 2003, 17:1922-1924.
291. Wang M.J., Lin W.W., Chen H.L., Chang Y.H., Ou H.C., Kuo J.S., Hong J.S., Jeng K.C. Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur. J. Neurosci. 2002, 16:2103-2112.
292. Liu Y., Qin L., Li G., Zhang W., An L., Liu B., Hong J.S. Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J. Pharmacol. Exp. Ther. 2003, 305:212-218.
293. Breidert J., Callebert M.T., Heneka G., Landreth J.M., Launay, Hirsch E.C. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 2002, 82:615-624.
294. Adeosun S.O., Hou X., Jiao Y., Zheng B., Henry S., Hill R., He Z., Pani A., Kyle P., Ou X., Mosley T., Farley J.M., Stockmeier C., Paul I., Bigler S., Brinton R.D., Smeyne R., Wang J.M. Allopregnanolone reinstates tyrosine hydroxylase immunoreactive neurons and motor performance in an MPTP-lesioned mouse model of Parkinson's disease. PLoS One 2012, 7:e50040.
295. D'Astous M., Mickley K.R., Dluzen D.E., Di Paolo T. Differential protective properties of estradiol and tamoxifen against methamphetamine-induced nigrostriatal dopaminergic toxicity in mice. Neuroendocrinology 2005, 82:111-120.
296. Hemmer K., Fransen L., Vanderstichele H., Vanmechelen E., Heuschling P. An in vitro model for the study of microglia-induced neurodegeneration: involvement of nitric oxide and tumor necrosis factor-alpha. Neurochem. Int. 2001, 38:557-565.
297. Le W., Rowe D., Xie W., Ortiz I., He Y., Appel S.H. Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J. Neurosci. 2001, 21:8447-8455.
298. Iravani M.M., Kashefi K., Mander P., Rose S., Jenner P. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 2002, 110:49-58.
299. Arimoto T., Bing G. Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. Neurobiol. Dis. 2003, 12:35-45.
300. Benner E.J., Banerjee R., Reynolds A.D., Sherman S., Pisarev V.M., Tsiperson V., Nemachek C., Ciborowski P., Przedborski S., Mosley R.L., Gendelman H.E. Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One 2008, 3:e1376.
301. + T cells from copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neuroimmunol. 2007, 183:60-68.
302. Kohutnicka M., Lewandowska E., Kurkowska-Jastrzebska I., Członkowski A., Członkowska A. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology 1998, 39:167-180.
303. Klegeris A., McGeer P.L. R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition. Exp. Neurol. 2000, 166:458-464.
304. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 2009, 8:382-397.
305. Isaacs A., Lindenmann J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 1957, 147:258-267.
306. Isaacs A., Lindenmann J., Valentine R.C. Virus interference. II. Some properties of interferon. Proc. R. Soc. Lond. B Biol. Sci. 1957, 147:268-273.